

Attorney Docket No. Le A 36 036

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hilmar Bischoff, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP2003/011619

Title: 7H-Dibenzo[B,G][1,5]Dioxocin-5-one Derivatives and Use Thereof

**MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450**

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying modified form PTO-1449. A copy of the International Search Report is also enclosed for your reference.


**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,



Dr. Tilman Breitenstein
Limited Recognition Under 37 C.F.R. § 11.9(b)

Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516
Telephone: (203) 812-2226
Facsimile: (203) 812-6459

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.